2005
DOI: 10.1186/1475-2840-4-6
|View full text |Cite
|
Sign up to set email alerts
|

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

Abstract: Background: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activitygamma (PPARγ) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
40
0
15

Year Published

2006
2006
2017
2017

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 168 publications
(56 citation statements)
references
References 39 publications
1
40
0
15
Order By: Relevance
“…It has previously been reported that Angiotensin Ⅱ receptor blockers (ARBs) have a positive effect on reactive oxygen species production and mitochondrial function in animals (for review see [68] ). It has been reported that ARBs have different effects on glucose homeostasis in hypertensive patients with the metabolic syndrome [69] . Patients treated with telmisartan showed an improvement in HOMA-IR and HbA1c (surrogate measures of insulin sensitivity [70] ), whereas patients treated with losartan showed no improvement [69] .…”
Section: Endurance Trainingmentioning
confidence: 99%
See 1 more Smart Citation
“…It has previously been reported that Angiotensin Ⅱ receptor blockers (ARBs) have a positive effect on reactive oxygen species production and mitochondrial function in animals (for review see [68] ). It has been reported that ARBs have different effects on glucose homeostasis in hypertensive patients with the metabolic syndrome [69] . Patients treated with telmisartan showed an improvement in HOMA-IR and HbA1c (surrogate measures of insulin sensitivity [70] ), whereas patients treated with losartan showed no improvement [69] .…”
Section: Endurance Trainingmentioning
confidence: 99%
“…It has been reported that ARBs have different effects on glucose homeostasis in hypertensive patients with the metabolic syndrome [69] . Patients treated with telmisartan showed an improvement in HOMA-IR and HbA1c (surrogate measures of insulin sensitivity [70] ), whereas patients treated with losartan showed no improvement [69] . Whether these improvements can be explained by improvements in mitochondrial function is at the moment impossible to say.…”
Section: Endurance Trainingmentioning
confidence: 99%
“…К их дополнительным преимуществам относится спо-собность к блокированию симпатической активно-сти. Доказана эффективность БРА в уменьшении ИР, а также улучшении показателей углеводного, липид-ного и пуринового обмена [61].…”
Section: ожирение и метаболизмunclassified
“…По объединенным данным исследований PRoFESS/TRANSCEND, при использовании телми-сартана выявлено снижение риска развития СД на 16% в сравнении с плацебо [21]. Такой эффект телмисартана связывают с его способностью стиму-лировать PPAR-γ, которая у этого препарата выра-жена больше, чем у других представителей класса БРА [22,23]. Стимулируя PPAR-γ, телмисартан акти-вирует пролиферацию пероксисом и регулирует вну-триклеточный метаболизм липидов и глюкозы, уменьшает воспаление, обладает антиоксидантными и антипролиферативными свойствами.…”
Section: Combination Antihypertension Therapy: the "Underresearched" unclassified
“…Этот ком-плекс эффектов определяет его положительное влия-ние на эндотелий сосудов, уровень глюкозы, тригли-церидов, чувствительность к инсулину и антифибро-тическое действие. Имеются данные об уменьшении инсулинорезистентности тканей за счет стимуляции ядерных PPAR-γ клеток жировой, мышечной ткани и гепатоцитов [22,23]. Считается, что агонизм к PPAR-γ позволяет телмисартану не только подав-лять гиперактивацию РААС, но и уменьшать актив-ность симпатической нервной системы [24].…”
Section: Combination Antihypertension Therapy: the "Underresearched" unclassified